Dextromethorphan protects male but not female mice with brain ischemia

Departments of aNeurology and Developmental Medicine bNeuroscience, Kennedy Krieger Research Institute Departments of cNeurology dPediatrics eNeuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Neuroreport (Impact Factor: 1.52). 09/2006; 17(12):1319-22. DOI: 10.1097/01.wnr.0000220136.98918.41
Source: PubMed


The non-competitive N-methyl-D-aspartate receptor antagonist dextromethorphan is protective against some types of brain injury. Unilateral carotid ligation in postnatal day 12 CD1 mice produces ischemic brain injury. To evaluate the neuroprotective potential of dextromethorphan against ischemic injury in the immature brain, seven litters of postnatal day 12 CD1 mice received either dextromethorphan or vehicle after a unilateral carotid ligation. Only the male pups were protected, and brain injury was unchanged in the female pups treated with dextromethorphan. These results suggest that dextromethorphan neuroprotection against ischemic injury in the immature brain is sex-dependent.

8 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A parallel constrained coding scheme is considered where p-blocks of raw data are encoded simultaneously into q tracks such that the contents of each track belong to a given constraint S. It is shown that as q increases, there are parallel block-decodable encoders for S whose coding ratio p/q converges to the capacity of S. Examples are provided where parallel coding allows block-decodable encoders, while conventional coding, at the same rate, does not. Parallel encoders are then applied as building blocks in the construction of block-decodable encoders for certain families of two-dimensional constraints
    IEEE Transactions on Information Theory 06/2002; 48(5-48):1009 - 1020. DOI:10.1109/18.995538 · 2.33 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cerebral palsy (CP) and related developmental disorders are more common in males than in females, but the reasons for this disparity are uncertain. Males born very preterm also appear to be more vulnerable to white matter injury and intraventricular hemorrhage than females. Experimental studies in adult animals and data from adult patients with stroke indicate that sex hormones such as estrogens provide protection against hypoxic-ischemic injury, and the neonatal brain is also influenced by these hormones. However, hormonal influences on the fetus and neonates are substantially different from those on adults. Recent data from neonatal rodents subjected to hypoxia-ischemia also demonstrate differences between males and females. Knockout of the gene for poly (ADP-ribose) polymerase (PARP-1), a major step in the cascade of injury, protected male but not female mouse pups from hypoxic-ischemic injury. Other reports demonstrated major differences between male and female neurons grown separately in cell culture, suggesting that sex differences in the fetal or neonatal period result from intrinsic differences in cell death pathways. This new information indicates that there are important neurobiological differences between males and females with respect to their response to brain injuries. This information is relevant to understanding the pathogenesis of CP as well as to the design of future clinical trials of potential neuroprotective strategies.
    Developmental Medicine & Child Neurology 02/2007; 49(1):74-8. DOI:10.1111/j.1469-8749.2007.0199a.x · 3.51 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Recombinant human erythropoietin (rEpo) is neuroprotective in neonatal models of hypoxic-ischemic brain injury. However, the optimal rEpo dose, dosing interval, and number of doses for reducing brain injury are still undetermined. We compared the neuroprotective efficacy of several subcutaneous rEpo treatment regimens. Seven-day-old rats underwent unilateral carotid ligation plus 90 min 8% hypoxia. Treatment began immediately after injury. Treatment regimens examined included 1, 3, or 7 daily subcutaneous injections of either 0 (vehicle), 2,500, 5,000, or 30,000 U/kg rEpo. Gross brain injury, neuronal apoptosis (TUNEL), and gliosis (glial fibrillary acidic protein) were assessed at 48 h or 1 wk post injury. Immunoreactive cells and brain injury were quantified for statistical comparison to vehicle controls. rEpo treatment reduced brain injury, apoptosis, and gliosis, in a dose-dependent U-shaped manner at both 48 h and 1 wk. Neither one injection of 2,500, seven injections of 5,000, or three injections of 30,000 U/kg rEpo were protective. Three doses of 5,000 and one dose of 30,000 U/kg rEpo were most protective at both time intervals. rEpo provides dose-dependent neuroprotection. Of the regimens tested, three doses of 5,000 U/kg was optimal because it provided maximal benefit with limited total exposure.
    Pediatric Research 05/2007; 61(4):451-5. DOI:10.1203/pdr.0b013e3180332cec · 2.31 Impact Factor
Show more